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Background. Much has been written recently about the potential hazards versus benefits of antibacterial
(biocide)–containing soaps. The purpose of this systematic literature review was to assess the studies that have
examined the efficacy of products containing triclosan, compared with that of plain soap, in the community setting,
as well as to evaluate findings that address potential hazards of this use—namely, the emergence of antibiotic-
resistant bacteria.
Methods. The PubMed database was searched for English-language articles, using relevant keyword combi-
nations for articles published between 1980 and 2006. Twenty-seven studies were eventually identified as being
relevant to the review.
Results. Soaps containing triclosan within the range of concentrations commonly used in the community
setting (0.1%–0.45% wt/vol) were no more effective than plain soap at preventing infectious illness symptoms and
reducing bacterial levels on the hands. Several laboratory studies demonstrated evidence of triclosan-adapted cross-
resistance to antibiotics among different species of bacteria.
Conclusions. The lack of an additional health benefit associated with the use of triclosan-containing consumer
soaps over regular soap, coupled with laboratory data demonstrating a potential risk of selecting for drug resistance,
warrants further evaluation by governmental regulators regarding antibacterial product claims and advertising.
Further studies of this issue are encouraged.
In October 2005, the Non-Prescription Drug Advisory
Committee of the US Food and Drug Administration
(FDA) was convened to discuss the potential benefits
and risks associated with antiseptic products marketed
for consumer use, such as soaps labeled as “antibac-
terial.” The conclusion of the FDA meeting resulted in
a call for further research regarding the risks and ben-
efits of specific consumer antiseptic products used in
the community setting. Much of the debate regarding
consumer antiseptic products has focused on the use
of “antibacterial soaps” that contain the active ingre-
dient triclosan. The majority of consumer liquid hand
soaps labeled as “antibacterial” contain triclosan [1],
and, although the FDA does not formally regulate the
levels of triclosan used in consumer products, most of
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the popular liquid hand soap brands contain between
0.1% and 0.45% weight/volume (wt/vol). A chemically
related compound, triclocarban, is used in antibacterial
bar soap formulations.
Triclosan is a phenoxyphenol antimicrobial that is
marketed as an “antibacterial” ingredient in consumer
hygiene products, but it also has some antiviral and
antifungal activity [2]. It is bacteriostatic at low con-
centrations and bactericidal at high concentrations [3].
Triclosan has been shown to inhibit the growth of both
gram-positive and gram-negative bacteria in situ, with
varying effectiveness across bacterial species [2]. For
example, triclosan is relatively ineffective at inhibiting
the growth of gram-negative bacteria such as Pseudo-
monas aeruginosa and Serratia marcescens [2]. Although
the bactericidal activity of triclosan involves some non-
specific killing mechanisms, research findings suggest
that the bacteriostatic action occurs by inhibiting a spe-
cific bacterial target, known as the “enoyl-acyl carrier
protein reductase” [4–6]. Triclosan shares this bacterial
biosynthetic fatty acid pathway target with the antibi-
otic isoniazid [5]. These findings have led researchers
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to explore whether triclosan may influence the emergence of
resistance to antibiotics [7–9].
Similar to the methods used for testing clinical antibiotic
resistance, a MIC method is used to assess reduced susceptibility
to triclosan. Currently, there are no clinically meaningful MIC
cutoff points for monitoring resistance to biocides, and, there-
fore, the term “reduced susceptibility” is commonly used when
discussing bacterial tolerance to triclosan exposure. Similar to
their resistance to antibiotics, bacteria may be intrinsically re-
sistant to triclosan via mechanisms of impermeability, efflux
pumps, biofilms, and enzyme inactivation. The decreased sus-
ceptibility of greatest concern regarding triclosan is acquired
tolerance/resistance. The resistance mechanisms are similar to
those producing antibiotic resistance and include mutations at
the drug target site, chromosome-mediated drug efflux, and
overexpression of the target protein. Acquired bacterial resis-
tance mechanisms may lead to an increase in MICs to anti-
biotics as well as to triclosan [7, 9, 10].
Although several investigators have reviewed studies exam-
ining the mechanisms of antiseptic resistance [7, 9–16], there
are few systematic reviews that have attempted to summarize
the potential risks associated with triclosan in the context of
the purported effectiveness of this antibacterial ingredient used
in hygiene products in the community setting. The efficacy of
soap containing triclosan generally refers to the additional level
of effectiveness beyond the ability of plain soap to simply re-
move transient organisms via surfactants and the mechanical
action of the wash procedure [17]. The level of effectiveness
may be measured at the microbiological level or at the pop-
ulation level, as added protection against bacterial contami-
nation or the occurrence of common infectious illnesses. Risks,
on the other hand, include the potential for bacteria to become
unsusceptible to triclosan, for the emergence of cross-resistance
to antibiotics, and for the ingredients to become toxic to the
environment and to humans.
Only in the past 5 years has the effectiveness of triclosan for
preventing infectious illnesses in the community setting been
assessed; the first studies of which we are aware were published
in 2002 [18]. In this review, we identify and summarize the
studies examining the efficacy of triclosan by reviewing research
that has examined the effectiveness of these consumer antiseptic
soaps at reducing the incidence of infectious illnesses in the
community setting and bacterial counts on the skin. Second,
we identify and summarize the literature that examines whether
there is a potential risk associated with use of hygiene products
containing triclosan in relation to emergence of microbes that
are less susceptible to triclosan and/or resistant to clinically
used antibiotics. Finally, we weigh the evidence regarding the
risks and benefits and conclude with recommendations for fur-
ther research and for examining the implications of the current
data on regulation of consumer products containing triclosan.
METHODS
The PubMed database was searched for English-language ar-
ticles published during the period January 1980–July 2006, us-
ing keyword combinations for each search strategy. Keywords
included “absence,” “absent*,” “alcohol,” “antibacterial clean-
ing,” “antibacterial soap,” “antiseptic,” “behavior,” “child care,”
“child day care,” “child morbidity,” “child*,” “cold,” “com-
munity,” “day care,” “day care center,” “diarrhea*,” “diar-
rhoea,” “education,” “hand,” “hand sanitizer,” “hand wash,”
“hand wash*,” “infection control,” “infectious disease,” “in-
fectious illness,” “infectious*,” “intervention,” “health inter-
vention,” “hygiene,” “hygiene education,” “infants,” “infect*,”
“morbidity,” “preschool,” “prevent*,” “respiratory,” “sanita-
tion,” “soap,” “school,” “triclocarban,” “triclosan,” “wash*,”
and “water.” An asterisk (*) denotes a truncated search method
in which PubMed seeks the first 600 variations of terms with
the same root (for example, “infect*” would result in a search
for “infect,” “infection,” “infectious,” etc.).
The search results were scanned for research articles and
systematic reviews. In addition, the reference lists in retrieved
review papers were searched for related articles. Articles that
focused on triclosan in dentifrice were excluded, because the
introduction of triclosan in dentifrice was relatively recent
(1997), compared with its introduction in topical antiseptics
(1960s) [3, 19].
Our review of the literature was limited to studies that al-
lowed comparison of the effectiveness of triclosan-containing
soap with that of plain soap. We also included studies that
assessed the effectiveness of triclocarban soap, because this is
a chemically similar compound found in most antibacterial bar
soaps available to consumers. The study outcomes included
reported or diagnosed gastrointestinal infection (such as shi-
gellosis) or upper respiratory tract infection (such as pneu-
monia), general gastrointestinal and/or respiratory symptom(s)
of infection (such as diarrhea or runny nose), gastrointestinal
and/or respiratory infectious symptom–related absences (such
as school absence for a “cold”), and/or skin infections. Micro-
biological end points were limited to studies that examined the
effect of antibacterial soap containing triclosan on bacterial
reductions on the hand, compared with plain soap. Studies
conducted among volunteer participants that were not asso-
ciated with the clinical setting were included if they were con-
ducted in natural settings or in a controlled laboratory envi-
ronment. Because this review focused on the use of hand
products containing triclosan in the community setting, articles
were excluded if the setting was a health care facility, such as
a hospital or residential nursing home, or if the study subjects
were health care workers. Lastly, studies in which triclosan was
combined with other antiseptic ingredients, such as alcohol or
iodine, were excluded, because it would not have been possible
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to estimate the independent effects of triclosan compared with
plain soap in these studies [20].
To review the literature associated with risks, articles were
included if they (1) assessed mechanisms of cross-resistance,
using serial culture adaptation methodologies and/or genetic
manipulation of the bacterial molecular target site of triclosan;
(2) assessed levels of susceptibility to triclosan among bacterial
isolates obtained from humans in the community setting; or
(3) examined the statistical association between in-use exposure
to triclosan and reduced susceptibility to triclosan and/or an-
tibiotic resistance among humans living in the community
setting.
Using available data from the retrieved studies, we sum-
marized the findings regarding the efficacy of triclosan for re-
ducing infectious illness symptoms and bacterial growth on
skin. Next, we summarized the studies examining in situ mech-
anisms of reduced susceptibility to triclosan and cross-resis-
tance with antibiotics. In addition, we summarized the studies
that examined the association between the use of triclosan and
the emergence of antibiotic resistance among individuals living
in the community setting. Lastly, the strengths and limitations
of the studies were assessed by considering methods related to
design and conduct, such as sample size and masking of treat-
ment from study participants.
RESULTS
The PubMed search identified 1793 citations. On the basis of
our inclusion criteria, we identified a total of 27 studies that
examined either the effectiveness of triclosan or the risks of
antibiotic resistance associated with exposure to triclosan.
Efficacy of triclosan. We identified 4 community-based
randomized intervention studies [18, 21–23] providing infor-
mation on the effectiveness of consumer soaps containing tri-
closan or triclocarban compared with that of plain soap (table
1). Three of these studies were conducted in Pakistan, and 1
was conducted in an urban setting in the United States. The
study sample sizes ranged from 162 to 600 household units,
and all households were required to include a child 4 years
of age. Interventions included household member use of con-
sumer-available bar soap containing 1.2% triclocarban (wt/vol)
or liquid hand soap containing 0.2% triclosan (wt/vol) over a
1-year period. The outcomes recorded infectious illness symp-
toms such as cough, fever, diarrhea, and skin infections. None
of these studies included the collection of clinical samples for
laboratory identification of the etiologic agent associated with
illness symptoms. All 4 studies showed no significant reduction
in illness symptoms among household members associated with
the use of the biocide-containing soap versus plain soap.
We identified 9 studies that examined the effectiveness of
soap containing triclosan versus plain soap in reducing bacterial
levels on the hands (table 1) [24–32]. The majority of the
microbiological effectiveness studies ( ) were conductedn p 8
in a controlled laboratory setting [24, 26–32], and 1 was con-
ducted under natural conditions in the household setting [25].
Study sample sizes ranged from 10 to 238 subjects, and study
subjects were characterized as nonclinical volunteers. Slightly
fewer than half (4/9) of the studies mentioned the use of ran-
domization procedures, and only 22% reported masking of
study treatments. Most of the studies examined the normal
skin flora as the outcome, but 2 of the 9 studies used artificial
contamination [24, 32] procedures, by inoculating the skin of
volunteers with S. marcescens. Approximately half (5/9) of the
microbiological studies compared soap with at least 1.0% tri-
closan (wt/vol) versus plain soap, whereas the others utilized
a concentration of 0.3% triclosan (wt/vol) in the comparison.
Five of the 9 studies reported a significant reduction in bacterial
counts on hands in association with the use of triclosan-con-
taining soap versus plain soap. All but 1 of these 5 studies
utilized soap with a relatively high concentration of triclosan,
1.0% [29–31], and 2 of the 5 studies reported a significant
reduction only after multiple hand washes [24, 31], over mul-
tiple hand-washing episodes [24, 31], or after washing for 30
s [24, 31]. Only 1 study assessing triclosan at a concentration
of 0.3% wt/vol (a concentration closer to the 0.1%–0.45% wt/
vol found in many consumer antibacterial soaps) reported a
significant reduction in bacterial counts, and this reduction was
observed only after 18 hand washes per day, for 30 s each, over
5 consecutive days [31].
Risks associated with triclosan. Our search identified 11
laboratory studies assessing the influence of triclosan exposure
on the emergence of triclosan-tolerant species and cross-resis-
tance to clinical antibiotics (table 2). A range of bacteria was
examined, including gram-negative and gram-positive species;
commonly studied species included Escherichia coli, Staphylo-
coccus aureus, and Salmonella enterica. Seven of the 11 studies
demonstrated cross-resistance to 1 antibiotic for at least 1 of
the bacterial species examined (table 2). Commonly assessed
antibiotics included isoniazid, ciprofloxacin, erythromycin, tet-
racycline, chloramphenicol, ampicillin, and methicillin. Three
of 11 studies reported an increase in MICs to triclosan among
bacterial species but did not demonstrate cross-resistance to
clinically used antibiotics. One study examining E. coli reported
no evidence of increased tolerance to triclosan or cross-resis-
tance to antibiotics [39]. Given the variety of bacterial species
and antibiotics tested across studies, it was not possible to assess
whether a consistent pattern of cross-resistance for specific or-
ganism/antibiotic combinations existed.
We identified only 3 studies that examined the emergence
of antibiotic resistance associated with use of triclosan in the
community setting (table 3). The first study included a con-
venience sample of 60 households [43] divided into those that
reported using 1 antibacterial hygiene products and those
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Table 1. Studies comparing the efficacy of antibacterial soap containing triclosan (Ts) with that of plain soap.




of Tc or Ts)
Nonmedicated plain
soap control group,
liquid/bar Outcome(s) Results (antibacterial soap vs. plain soap)
Infectious illness studiesa
Luby et al. [21]b 600 households Bar (1.2% Tc) Bar Multiple symptomsc Not statistically significant: RR of symptoms—
assessed independently—all ∼1
Larson et al. [22] 240 households Liquid (0.2% Ts) Liquid Multiple symptomsd Not statistically significant: RR of 0.96 (95% CI,
0.82–1.12)
Luby et al. [23]b 600 households Bar (1.2% Tc) Bar Diarrhea symptoms Not statistically significant: mean incidence of
diarrhea was 2.02 (antibacterial soap) vs. 1.91
(plain soap)
Luby et al. [18] 162 households Bar (1.2% Tc) Bar Impetigo incidence Not statistically significant: incidence density
ratioe of 0.77 (95% CI, 0.48–1.24)
Microbiological studies
Sickbert-Bennett et al. [24] 10 volunteers Liquid (1.0% Ts) Liquid Reduction in mean log10 Serratia
marcescens colony-forming units af-
ter artificial contamination of hands
Not statistically significant: after 1 episode of
hand hygiene, 1.90 (antibacterial soap) vs. 2.00
(plain soap) log10 cfu reduction
Statistically significant: after 10 episodes of hand
hygiene, 2.49 (antibacterial soap) vs. 1.68 (plain
soap) log10 cfu ( ) reductionP ! .0001
Larson et al. [25] 238 primary care
givers
Liquid (0.2% Ts) Liquid Mean log10 bacterial colony-forming
units on hands
Not statistically significant: after 1 episode of
hand hygiene, 5.77 (antibacterial soap) vs. 5.62
(plain soap) log10 cfu ( )P 1 .28
Not statistically significant: after 1 year of use,
4.87 (antibacterial soap) vs. 4.93 (plain soap)
log10 cfu ( )P 1 .28
Faoagali et al. [26] 33 nonclinical staff Liquid (1.0% Ts) Liquid Mean difference in log10 colony-forming
units on hands
Not statistically significant: after an immediate
episode of hand hygiene or after a second
hand hygiene episode 3 h later, compared with
baseline, mean difference, 0.0564 log10 cfu
( )P 1 .05
Not statistically significant: after 5 days of hand
washing 3 times/day, 4.87 (antibacterial soap)
vs. 4.93 (plain soap) log10 cfu (all )P 1 .28
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Miller et al. [27] 20 workers in the
food industry
Liquid (0.3% Ts) Liquid Percentage reduction in mean log10 bac-
terial colony-forming units on hands
Not statistically significant: after 1 episode of
hand hygiene, 48.2% (antibacterial soap) vs.
41.7% (plain soap) reduction
Namura et al. [28] 7 healthy adult men
without eczema
Liquid (0.3% Ts) Liquid Percentage reduction in mean log10 bac-
terial colony-forming units on hands
Not statistically significant: after washing for 3
min, 32.86% (antibacterial soap) vs. 44.93%
(plain soap) reduction
Leyden et al. [29] 20 students and
employees of a
university
Liquid (1.0% Ts) Liquid Percentage change in mean log10 bac-
terial colony-forming units on hands
Statistically significant: after 30-s hand wash,
48.3% (antibacterial soap) vs. 21.9% (plain
soap) reduction ( )P ! .001
Statistically significant: after 3-min hand wash,
70.1% (antibacterial soap) vs. 31.9% (plain
soap) reduction ( )P ! .05
Bendig [30] 20 volunteer labora-




Liquid (2.0% Ts) Bar Mean log10 reduction in bacterial
colony-forming units on hands
Statistically significant: after 5 sequential washes
spaced 20 min apart, 0.79 (antibacterial soap)
vs. 0.16 (plain soap) log10 cfu reduction (P !
).001
Larson et al. [31] 40 nonmedical
volunteers
Liquid (0.3% Ts) Liquid Mean log10 bacterial colony-forming
units on hands
Not statistically significant: after 1 day of use at 6
hand washes/day, 6.17 (antibacterial soap) vs.
5.71 (plain soap) log10 cfu ( )P 1 .05
Not statistically significant: after 1 day of use at
18 hand washes/day, 6.11 (antibacterial soap)
vs. 5.75 (plain soap) log10 cfu ( )P 1 .05
Not statistically significant: after 5 days of use at
6 hand washes/day, 5.42 (antibacterial soap) vs.
5.25 (plain soap) log10 cfu ( )P 1 .05
Statistically significant: after 5 days of use at 18
hand washes/day, 4.56 (antibacterial soap) vs.
5.45 (plain soap) log10 cfu ( )P ! .05
Bartzokas et al. [17] 12 volunteers Liquid (1.5% Ts) Liquid Reduction in mean log10 S. marcescens
colony-forming units after artificial
contamination of hands
Statistically significant: significant reductions were
observed after 1 (2.91 log10 cfu), 4 (3.22 log10
cfu), 7 (3.50 log10 cfu), and 10 (3.78 log10 cfu)
episodes of hand hygiene with antibacterial
soap, compared with 1 episode with plain soap
(2.72 log10 cfu) (all )P ! .01
NOTE. RR, relative risk; Tc, triclocarban.
a All infectious illness studies followed participants for 1 year.
b These studies did not provide a statistical comparison of the antibacterial treatment arm versus the plain soap treatment arm, so we computed statistical comparisons using the data available from the study. It
was not possible to control for clustering effects in these calculations.
c Infectious illness symptoms such as diarrhea, cough, congestion, pneumonia, and impetigo.
d Infectious illness symptoms such as diarrhea, cough, sore throat, fever, and vomiting.
e Models adjusted for covariates.
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Table 2. Triclosan (Ts) adaptation and antibiotic cross-resistance studies.
Reference Types of bacterial species Exposure parameters Results
Ledder et al. [33]a Coagulase-negative Staphylococcus species,
Enterobacter asburiae, Escherichia coli, Kleb-
siella species, Salmonella enterica (sero-
types Enteritidis, Typhimurium, and Infantis),
Stenotrophomonas maltophilia
Ts/antibioticsb Ts MIC was increased among E. coli, Klebsiella species, and S. maltophilia only; among bacteria
with high MICs to Ts, there was no increase in MICs to 4 antibiotics after exposure to Ts
Sanchez et al. [34] S. maltophilia Ts/antibioticsb Ts-adapted mutants showed reduced susceptibility to tetracycline and chloramphenicol but not to
tobramycin, compared with the wild-type strain; these strains overexpressed the multidrug-
resistance pump SmeDEF
Braoudaki and Hilton [35]a S. enterica (serotypes Enteritidis, Typhimurium,
and Virchow)
Ts/antibioticsb S. enterica serotype Virchow became more tolerant to Ts and erythromycin after gradual exposure
to higher concentrations of these agents (up to 1024 mg/mL) over 6 days; adaptive
resistance to Ts and erythromycin was stable for at least 30 days of passage in Ts/antibiotic-
free medium
Braoudaki and Hilton [36]a E. coli O111:H24, E. coli O157:H7, E. coli
O55, E. coli K-12
Ts/antibioticsb Four sublethal exposures of E. coli O157:H7 led to an increase in MICs to Ts of 0.25 mg/mL
to 1024 mg/mL; Ts-adapted E. coli O157:H7 demonstrated cross-resistance to a number of anti-
biotics, including amoxicillin, chloramphenicol, ciprofloxacin, tetracycline, and trimethoprim;
E. coli K-12 and E. coli O55 adapted to Ts showed reduced susceptibility to chloramphenicol
and trimethoprim, respectively; other strains did not demonstrate cross-resistance
Braoudaki and Hilton [37] E. coli O157:H7, E. coli K-12, S. enterica (sero-
types Enteritidis, Typhimurium, and Virchow)
Ts/antibioticsb An increase in MICs to Ts and cross-resistance with erythromycin and ciprofloxacin was demonstrated
for E. coli O157:H7; adaptation of E. coli O157:H7 to erythromycin also led to an increase
in MICs; S. enterica serotype Virchow demonstrated reduced susceptibility to Ts and cross-
resistance with erythromycin after serial passage
Randall et al. [38] S. enterica Ts/antibioticsb Increase in the mean frequency of mutations that confer resistance to ampicillin
Walsh et al. [39] E. coli Tcc No evidence of increased tolerance to Ts
Fraise [40] MRSA Tsd Threefold increase in MICs to Ts
Chuanchuen et al. [41] Pseudomonas aeruginosa Ts/antibioticsb A 94-fold increase in MICs to ciprofloxacin was observed among strains that showed high levels
of tolerance to Ts
Suller and Russell [42] Methicillin-susceptible S. aureus, MRSA Ts/antibioticsb No consistent pattern between high Ts MICs and antibiotic-resistance profiles after exposure over
1 month; 2 of 3 MRSA strains that were resistant to mupirocin and several other antibiotics
were also less susceptible to Ts; however, coresistance with mupirocin was not plasmid
mediated
McMurry et al. [5] Mycobacterium smegmatis Ts/isoniazide A mutation originally selected for on isoniazid also mediated Ts resistance, and vice versa
NOTE. MRSA, methicillin-resistant Staphylococcus aureus; Tc, triclocarban.
a This study also looked at drain bacteria; this information is not presented here.
b Repeated exposure to sublethal Ts concentrations in nutrient broth and subsequent exposure to several antibiotics.
c Repeated exposure to sublethal Tc concentrations in nutrient broth.
d Repeated exposure to sublethal Ts concentrations in nutrient broth.
e Repeated exposure to sublethal Ts concentrations and subsequent exposure to isoniazid
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Table 3. Community-level studies of the relationship between exposure to triclosan in home hygiene products and antibiotic resistance.
Reference
Sample size
(location) Isolate source Organism(s) Antibiotics, no. Results
Cole et al. [43] 60 households; 8
bacterial isolates
(US, UK)
Hands of 1–2 household members
reporting use of antibacterial products vs.
those reporting use of nonantibacterial
products
Staphylococcus aureus 18 Comparable triclosan MICs among antibacterial vs. non-
antibacterial user homes;a no patterns discerned with
antibiotic susceptibilities
Aiello et al. [44] 240 individuals;
628 bacterial iso-
lates (US)
Hands of primary caregivers in house-










8 Not statistically significant: several staphylococcal species
showed reduced susceptibility to triclosan
Aiello et al. [45] 240 individuals (US) Hands of antibacterial vs. nonantibacterial
user households
Carriage of 1 antibi-
otic-resistant
organismb
… Not statistically significant
a This study did not assess statistical significance because the number of final isolates for analysis was limited. Other bacterial isolates obtained in this study were from environmental sources within the
household and are not presented here. The authors reported that the results for the environmental isolates also showed no evidence of cross-resistance.
b The organisms were the same as those listed for Aiello et al. [44].
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that reported no use of antibacterial hygiene products. Bacteria
were isolated from the hands of household members and their
home environments. There was no information on the con-
centration or prevalence of triclosan-containing products
among the reported antibacterial-user households. Although
the sample size was not sufficient to make statistical compar-
isons, the authors of the study still concluded that there was
no association between use of antibacterial products and the
presence of antibiotic-resistant species among household mem-
bers and their environment.
The next 2 studies were derived from a randomized and
masked intervention trial of 238 households allocated to using
either 0.2% triclosan–containing liquid hand soap or plain
soap [44, 45]. Bacterial samples were obtained from the hands
of household members at baseline and after 1 year of using
the assigned hand hygiene product. Neither of these studies
demonstrated the emergence of antibiotic resistance associ-
ated with use, over a 1-year period, of the liquid hand soap
containing 0.2% triclosan compared with plain soap. The au-
thors did note that several species, such as P. aeruginosa and
some coagulase-negative staphylococcal species, demon-
strated unexpectedly high MICs to triclosan at both baseline
and the end of the year [44].
DISCUSSION
Triclosan has been used in personal hygiene products in the
United States since the 1960s, and this chemical is now the
most prevalent biocide ingredient in consumer liquid hand
soaps [1]. Our study is, to our knowledge, the first systematic
review of research assessing the risks and potential benefits
associated with the use of soaps containing triclosan in the
community setting. The available data do not support the ef-
fectiveness of triclosan for reducing infectious disease symp-
toms or bacterial counts on the hands when used at the con-
centrations commonly found in consumer antiseptic hand
soaps. The effectiveness was similar to that of plain soap in the
majority of studies, and a difference in the reduction of bacterial
levels on the hands was generally observed only after longer
hand washes with soap containing relatively high concentra-
tions of triclosan (i.e., 1.0% wt/vol). Regarding the risks as-
sociated with triclosan, we identified several studies that sup-
ported a relationship between exposure of bacteria to triclosan
in the laboratory and increased MICs to clinically utilized an-
tibiotics. In contrast, research conducted at the population level
showed little evidence of cross-resistance with antibiotics as-
sociated with household use of hygiene products containing
triclosan.
Hand hygiene is an important practice for reducing the trans-
mission of infectious illnesses in both the clinical and com-
munity setting [46, 47]. Although there are numerous studies
examining the efficacy of antimicrobial hand hygiene agents in
the clinical setting (reviewed in [46]), few have examined the
efficacy of biocide-containing hand hygiene products frequently
utilized in the community setting. The 4 available studies that
examined the efficacy of biocide-containing soap compared
with that of plain soap at reducing infectious illnesses showed
no significant differences in any of the infectious illness symp-
toms that were assessed [18, 21–23]. All of these studies were
large, randomized, 1-year intervention studies that included
rigorous follow-up of study participants and illness outcomes.
The study populations ranged in age, but all 4 studies required
households to have at least 1 child residing in the home. The
null findings were consistent across various study settings, rang-
ing from urban upper Manhattan to squatter settlements in
Pakistan. Even in areas with high rates of infectious illnesses,
such as the urban squatter settlements in Karachi, there was
little benefit associated with use of the soap containing triclo-
carban compared with plain soap.
None of these studies gathered clinical isolates for the iden-
tification of the biological agent associated with the illness
symptoms, so it is was not possible to assess whether the re-
ported symptoms were associated with organisms other than
bacteria, such as viruses. Triclosan is less effective against viral
agents [2]; therefore, it is possible that this ingredient showed
no impact on infectious illnesses in the household setting be-
cause a majority of the infectious etiologies may be associated
with viral pathogens. Still, when examining impetigo, for which
a viral etiology is unlikely, the results can be regarded more
decisively and suggest that triclosan provides little benefit for
reducing skin infections caused by bacteria in the community
setting [18]. Symptoms such as coughing, sneezing, fever, and
diarrhea are commonly observed for many of the significant
infectious illnesses observed in the community setting and may
be related to infection by viruses or bacteria [48]. Therefore,
the available community-based intervention studies suggest
that consumer products containing triclosan or triclocarban
are not effective against the most common infectious illnesses
affecting individuals in the community setting. For these rea-
sons, the public health utility of this antibacterial ingredient
for preventing common infectious illnesses, as a measure of
added protection beyond that afforded by plain soap use, has
not been shown. We were unable to identify any studies that
examined the efficacy of soaps containing triclosan among
other populations living in the community setting, such as
elderly or immunocompromised individuals. Therefore, it is
unknown whether soaps containing triclosan could provide
protection to groups potentially at higher risk for infection.
Many of the available bacterial reduction studies we reviewed
tested the efficacy of hand hygiene agents used for 30 s.
Similar to our review, others have shown that an increased
application time of various hand hygiene agents tends to result
in greater efficacy [49]. It is unlikely that a 30-s duration
Antibacterial Soap Use: Efficacy and Risks • CID 2007:45 (Suppl 2) • S145
reflects the normal hand-washing practices in the community
setting. Even health care professionals generally wash their
hands for a much shorter duration [46], and studies of hand
washing in the community setting indicate suboptimal hand-
washing practices [50].
Another factor that has been identified as an important pa-
rameter for enhancing the efficacy of antiseptic hand hygiene
agents is the concentration of the ingredient [49]. In our review,
the majority of studies that identified a significant reduction
in bacterial levels on the hands utilized soap with a concen-
tration of 1.0% triclosan. Other factors, such as experimental
contamination versus normal flora, may also lead to findings
of enhanced efficacy [49]. Likewise, we identified 2 studies that
used artificial contamination [24, 32], and both reported sig-
nificant reductions with the use of the soap containing triclosan,
compared with plain soap. Study design issues, such as a lack
of randomization to treatment arms and a lack of masking
among study subjects, may also have affected the findings in
some of these reports.
Collectively, the microbiological efficacy studies strongly sug-
gest that concentrations of triclosan used in consumer liquid
hand soaps do not provide a benefit over plain soap for re-
ducing bacterial levels found on the hands. Although some of
these studies were limited by study design flaws and variability
in testing procedures, the results regarding the lack of efficacy
were consistent among studies utilizing a concentration of tri-
closan found in most consumer liquid hand soaps.
Research regarding the risks associated with triclosan use has
primarily been conducted under controlled laboratory condi-
tions. This research has elucidated several molecular mecha-
nisms by which sublethal exposure to triclosan may lead to the
emergence of antibiotic-resistant bacteria among select species
[10]. Some of the triclosan-adapted bacterial species, such as
E. coli and P. aeruginosa, were able to grow in cultures with
concentrations of triclosan of up to 1024 mg/mL, which is close
to the concentrations added to many consumer soaps (i.e., 1000
mg/mL p 0.1% triclosan [wt/vol]). These findings were rela-
tively species specific, and much lower concentrations were
required to inhibit other organisms, such as staphylococci. Most
of the studies followed similar testing procedures for assessing
triclosan MICs and antibiotic resistance. However, the bacterial
species tested and the antibiotics assessed varied across studies.
This limited our ability to classify species- and antibiotic-spe-
cific cross-resistance patterns.
There have been only a few studies that have attempted to
assess the relationship between biocide-containing soap use and
the emergence of antibiotic resistance in the community setting.
Interestingly, the laboratory findings have not been corrobo-
rated among the intervention studies that were conducted in
the community under in-use conditions. There are several fac-
tors that might explain the discrepancy. First, laboratory testing
may not be generalizable to the emergence of antibiotic resis-
tance in the environment. Laboratory exposure conditions may
not mirror exposures that occur in the environment under
natural antiseptic use conditions. For example, it is possible
that bacterial species are exposed to higher concentrations of
triclosan under in-use conditions in household settings, com-
pared with relatively low concentrations often used in labo-
ratory studies. This may reduce the selective pressures for
antibiotic-resistant bacteria under in-use conditions in the
household. Second, selective pressures in the environment may
weed out cross-resistant organisms. Organisms that are selected
for resistance to both triclosan and antibiotics may be less fit
for survival in the environment when they are carrying plasmids
or must maintain costly genetic target mutations. Despite these
caveats, there are many examples with antibiotics in which
difficulty in obtaining resistant mutants in the laboratory did
not predict the relative ease of their emergence in the clinical
settings—for example, the fluoroquinolones.
Studies that have assessed whether there is an association
between exposure to products containing triclosan and anti-
biotic resistance in the community setting may not be large or
long enough to identify the emergence of antibiotic resistance.
For example, the 2 studies by Aiello et al. [44, 45] suggest a
trend toward resistance, but the studies were powered to detect
only moderate to high changes in antibiotic resistance over a
1-year period. The study by Cole et al. [43] examined only S.
aureus from the hands and had a relatively small number of
isolates available for comparison. Moreover, this study did not
randomize households to antiseptic product use or utilize
masking of treatments, which could reduce the ability to detect
a difference between user groups. The longest period of follow-
up among these studies was 1 year [44, 45], which may not
adequately reflect the time course for the development of re-
sistance associated with use of products containing triclosan.
Lastly, baseline levels of susceptibility to triclosan among bac-
terial species in the community setting are virtually unknown.
Thus, it is difficult to show a change if the organisms have
already achieved some level of resistance [44]. Most of the data
on MICs to triclosan are from studies of clinical laboratory
strains and culture type collections [2]. Consumer hygiene
products containing triclosan have been used since the 1960s,
and no formal surveillance mechanisms exist for assessing sus-
ceptibilities of bacteria to this agent in the community setting.
Further research is clearly needed to assess whether the emer-
gence of antibiotic resistance in the community setting is as-
sociated with the growing use of soaps containing triclosan.
Because our key aim in this review was to assess the efficacy
of and risks associated with the use of soaps containing triclosan
in the community setting, our literature search excluded studies
conducted in the clinical setting and those with health care
workers as study subjects. We did include 3 studies that did
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not specifically state the source of volunteers included in their
studies [20, 24, 28], because there was no indication that these
subjects were derived from the clinical setting. Because of our
focus on the community, we also excluded studies that assessed
exposure to triclosan in the clinical setting and the emergence
of antibiotic resistance. Two of the studies by Luby et al. [21,
23] did not present a statistical comparison of the antiseptic
treatment arm and the plain soap treatment arm, so we com-
puted statistical comparisons by use of the data available from
the study. Therefore, it is possible that these 2 studies did not
have adequate sample sizes to detect differences between treat-
ment arms using biocide-containing versus plain soap. The
differences, however, were very small and showed an even
slightly higher level of infectious illness symptoms, for some
of the outcomes, among the biocide-containing soap users
compared with the plain soap users.
Because hand soaps are one of the most commonly available
hygiene products containing triclosan, we limited our review
to studies that provided the results of exposure to these prod-
ucts among isolates of bacteria from humans. Two of the studies
included in our review isolated bacterial species from humans
and the environment [33, 43]. For these studies, we reported
only the results regarding the isolates from humans. Impor-
tantly, the results were similar regardless of isolate source [33,
43]. In addition, our search did not include studies that were
published in languages other than English. PubMed was the
only search database utilized; therefore, print sources such as
conference abstracts were excluded.
CONCLUSIONS
The results of our review call into question the marketing of
soaps containing triclosan as a product providing efficacy be-
yond the use of plain soap in the community setting. Soaps
containing triclosan at concentrations used in the community
setting (0.2% or 0.3% wt/vol) were generally no more effica-
cious than plain soap at preventing infectious illness symptoms
and reducing bacterial levels on the hands. Several studies dem-
onstrated laboratory evidence of triclosan-adapted cross-resis-
tance with antibiotics among multiple species of bacteria. There
are still too few studies that have been conducted in the com-
munity setting to adequately assess whether the emergence of
antibiotic resistance in that setting is associated with the use
of consumer soaps containing triclosan. Longitudinal studies
are needed to assess changes in levels of antibiotic resistance
associated with use of soap containing triclosan over time, and
large databases of isolates are required to examine within-spe-
cies changes in antibiotic-resistance profiles. Still, current find-
ings warrant actions by the FDA for evaluating consumer prod-
uct advertising claims. Future research should be directed at
addressing both the efficacy of and risks associated with the
use of triclosan. For instance, data are needed to assess whether
products containing triclosan provide an added level of pro-
tection among high-risk groups, such as immunocompromised
individuals living in the household setting.
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